Loading…
Loading…
LBLTF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LBLTF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LBLTF and 80,000+ other tickers.
See exactly how LBLTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LBLTF and 80,000+ other tickers.
Lattice Biologics Ltd. is a biotechnology firm focused on developing, manufacturing, and commercializing biological products designed for bone regeneration. These solutions are utilized globally across dental, spinal, and general orthopedic indications. The company's innovative offerings include novel amniotic fluid-based therapies such as AmnioBoost and AmnioBlast. In addition, their product line features a broad range of allografts, encompassing traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix varieties. These versatile products…
No recent news available.